Zurich Cantonal Bank’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
Other funds holding ABCL
BBA
TWC
ACH
DCM
Zurich Cantonal Bank's ABCL Position: Q1 2026 in Review
Zurich Cantonal Bank sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 2,633 shares — an estimated $9.01K sold.
Zurich Cantonal Bank first reported a position in ABCL in Q1 2025 and held it in 4 quarters. The position peaked at $13.2K in Q3 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.
- Zurich Cantonal Bank reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
- Zurich Cantonal Bank sold 2,633 AbCellera Biologics shares in Q1 2026, an estimated $9.01K.
- Zurich Cantonal Bank first reported a position in AbCellera Biologics in Q1 2025 and held it in 4 quarters.
- Zurich Cantonal Bank's AbCellera Biologics position peaked at $13.2K in Q3 2025.
- 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.
Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.